A Phase I/III, First in Human Trial of the Bruton's Tyrosine Kinase Inhibitor M7583 in Patients with B-Cell Malignancies

被引：2

作者：

Jurczak, Wojciech ^{[1
]}

Rule, Simon ^{[2
]}

Townsend, William ^{[3
]}

Tucker, David ^{[4
]}

Sarholz, Barbara ^{[5
]}

Scheele, Jurgen ^{[6
]}

Gribben, John G. ^{[7
]}

Zinzani, Pier Luigi ^{[8
]}

机构：

[1] Jagiellonian Univ, Dept Haematol, Krakow, Poland

[2] Plymouth Univ, Dept Haematol, Sch Med, Plymouth, Devon, England

[3] Univ Coll London Hosp NHS Fdn Trust, NIHR UCLH Clin Res Facil, London, England

[4] Torbay Hosp, Dept Haematol, Torquay, England

[5] Merck KGaA, R&D Global Biostat & Epidemiol, Darmstadt, Germany

[6] Merck KGaA, Global Clin Dev, Darmstadt, Germany

[7] Queen Mary Univ London, Ctr Haematooncol, Barts Canc Inst, London, England

[8] Ist Ematol, Bologna, Italy

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-112808

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4161

引用

页数：2

共 50 条

[21] Targeting Bruton's tyrosine kinase in B cell malignancies
Rudi W. Hendriks
Saravanan Yuvaraj
Laurens P. Kil
Nature Reviews Cancer, 2014, 14 : 219 - 232
[22] The safety of Bruton's tyrosine kinase inhibitors in B-cell malignancies: A systematic review
Arustamyan, Michael
Kibrik, Pavel
Hatipoglu, Dilara
Bungo, Brandon
Mentias, Amgad
Hill, Brian T.
Moudgil, Rohit
EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (06) : 696 - 710
[23] Targeting Bruton's tyrosine kinase in B cell malignancies
Hendriks, Rudi W.
Yuvaraj, Saravanan
Kil, Laurens P.
NATURE REVIEWS CANCER, 2014, 14 (04) : 219 - 232
[24] Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies
Marostica, Eleonora
Sukbuntherng, Juthamas
Loury, David
de Jong, Jan
de Trixhe, Xavier Woot
Vermeulen, An
De Nicolao, Giuseppe
O'Brien, Susan
Byrd, John C.
Advani, Ranjana
McGreivy, Jesse
Poggesi, Italo
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (01) : 111 - 121
[25] Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies
Eleonora Marostica
Juthamas Sukbuntherng
David Loury
Jan de Jong
Xavier Woot de Trixhe
An Vermeulen
Giuseppe De Nicolao
Susan O’Brien
John C. Byrd
Ranjana Advani
Jesse McGreivy
Italo Poggesi
Cancer Chemotherapy and Pharmacology, 2015, 75 : 111 - 121
[26] A Small Molecule Inhibitor of Bruton's Tyrosine Kinase Involved in B-Cell Signaling
Ratzon, Einav
Bloch, Itai
Nicola, Meshel
Cohen, Elad
Ruimi, Nili
Dotan, Nesly
Landau, Meytal
Gal, Maayan
ACS OMEGA, 2017, 2 (08): : 4398 - 4410
[27] Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies
Cheah, Chan Y.
Wickham, Nicholas
Yannakou, Costas K.
Lewis, Katharine L.
Hui, Chi-Hung
Tang, Pek Sang
Turpuseema, Tejasvi
Miskin, Hari P.
Tang, Jian-Ping
Normant, Emmanuel
Ricart, Alejandro D.
Tam, Constantine S.
BLOOD, 2019, 134
[28] Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies
Wiestner, Adrian
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) : 128 - 130
[29] ARQ 531, a novel and reversible inhibitor of Bruton's tyrosine kinase, displays favorable oral bioavailability and exposure in patients with B-cell malignancies
Hall, Terence
Yu, Yi
Eathiraj, Sudharshan
Stephens, Deborah
Flinn, Ian
Woyach, Jennifer
Schwartz, Brian
Savage, Ronald E.
CANCER RESEARCH, 2018, 78 (13)
[30] Development of a Bruton's tyrosine kinase (Btk) inhibitor - ONO-WG-307, a potential treatment for B-cell malignancies
Kozaki, Ryohei
Yoshizawa, Toshio
Yasuhiro, Tomoko
Mirjolet, Jean-Francois
Birkett, Joseph
Narita, Masami
Kawabata, Kazuhito
CANCER RESEARCH, 2012, 72

← 1 2 3 4 5 →